-transparent.png){kind=logo}
A pilot phase II study of a ifosfamide and vindesine combination of non-small cell lung cancer was conducted in the elderly patients and patients with reduced renal function. The combination consisted of ifosfamide, 2.3 g/m2, on day 1 through 3, and vindesine, 3 mg/m2, on day 1 and 8. Cycles were repeated at 4-week intervals. The dose of ifosfamide and vindesine was reduced in the elderly. Of 24 evaluable patients, one had a complete response and 8 had partial response, with an overall response rate of 37.5%. The projected median response duration was 6.8 months and the median survival for all patients was 15.1 months. The toxicity was tolerable with moderate myelosuppression. These results indicate that this combination chemotherapy is safe and effective for non-small cell lung cancer in the elderly patients and patients with reduced renal function and warrants further clinical trials.
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
October 1991,
Acta medica Okayama,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
January 1990,
Cancer chemotherapy and pharmacology,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
January 1988,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
September 1985,
Japanese journal of cancer research : Gann,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
April 2000,
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
May 1990,
Gan to kagaku ryoho. Cancer & chemotherapy,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
August 2003,
American journal of clinical oncology,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
January 1992,
Anticancer research,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
January 2003,
Oncology,
M Fujii, and
Y Segawa, and
S Matsutomo, and
K Genba
February 1999,
British journal of cancer,
